# A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

> **NCT03499899** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** LAG525
- **DRUG:** PDR001
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03499899
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2020-02-27
- **Final completion:** 2021-11-24
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499899, "A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03499899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*